Roivant's brepocitinib shows promising results for an inflammatory eye condition, following its recent clearance for dermatomyositis. Analysts suggest it could be a leading treatment option in this rare disease space.

Over 10 companies are advancing treatments for dermatomyositis, as highlighted in DelveInsight's latest pipeline report. The analysis reveals ongoing clinical strategies and upcoming therapeutics aimed at addressing this rare disease.

A recent study highlights the challenges of diagnosing extensive dystrophic calcinosis in patients with dermatomyositis, particularly when concurrent breast carcinoma is present. This research underscores the need for careful imaging interpretation in complex cases.

A recent study highlights the diagnostic potential of interferon-stimulated gene 15 (ISG15) muscle expression in dermatomyositis. This research could enhance diagnostic accuracy for this rare autoimmune disease.

Orsini will serve as the specialty pharmacy partner for Priovant's LISRAYA™ (brepocitinib), enhancing patient access to this innovative treatment. The drug was evaluated in the VALOR study, the largest placebo-controlled trial for dermatomyositis, indicating significant advancements in rare disease therapies.